PepPool: SARS‑CoV‑2 (SNMO), human

Human PBMC from COVID-19 convalescent individuals (first two from the left from individuals previously confirmed COVID-19 positive with PCR, and third from the left from individual recovering from COVID-19 symptoms) and healthy control. Cells (350,000 cells/well) were incubated overnight in the absence or presence of the SARS-CoV-2 S N M O defined peptide pool in the presence of anti-CD28 mAb. The number of cells secreting IFN-γ was analyzed by ELISpot and counted using MabtechIRIS.
Human PBMC from COVID-19 convalescent individuals (first two from the left from individuals previously confirmed COVID-19 positive with PCR, and third from the left from individual recovering from COVID-19 symptoms) and healthy control. Cells (350,000 cells/well) were incubated overnight in the absence or presence of the SARS-CoV-2 SNMO defined peptide pool in the presence of anti-CD28 mAb. The number of cells secreting IFN-γ and IL-2 was analyzed by FluoroSpot and counted using MabtechIRIS.

PepPool: SARS‑CoV‑2 (SNMO), human

3622-1

$475

Publications: 20
Documents
Questions?
Validated for our assays.

In stock

Delivery 4-9 business days

Shipping $0

Product specifications

Intended use

This peptide pool is intended for studying immune responses against SARS-CoV-2 (S, N, M, and O proteins) using immunoassays such as ELISpot and FluoroSpot. It induces cytokine secretion from antigen-specific human T cells. For research use only. Not for use in diagnostic procedures.

Serum/Plasma samples

Description
The SARS-CoV-2 (SNMO) defined peptide pool induces secretion of e.g., IFN-γ, IL-2, and granzyme B from human T cells. It contains 47 peptides from the human SARS-CoV-2 virus. The peptides are derived from the spike protein (S), nucleoprotein (N), membrane protein (M), and the open reading frame (ORF)-3a and ORF-7a proteins. The purity of the synthetic peptides range from 60-99%.

The peptide pool has been validated using human PBMC from COVID-19 convalescent individuals previously PCR-confirmed as SARS-CoV-2 positive.

Peptides included in the peptide pool are listed in the datasheet.

Recommendation

Product details

ProductPepPool: SARS-CoV-2 (SNMO), human
ApplicationT cell stimulation, ELISpot, FluoroSpot, Flow cytometry
ReactivityHuman
Supplied in

Lyophilized

Contents

Peptide pool with 47 peptides, 25 ug of each peptide. Supplied in one vial (lyophilized).

Shipping and Storage

Shipping

Shipped at ambient temperature.

Storage

Store at -20 °C or below upon receipt.

Human PBMC from COVID-19 convalescent individuals (first two from the left from individuals previously confirmed COVID-19 positive with PCR, and third from the left from individual recovering from COVID-19 symptoms) and healthy control. Cells (350,000 cells/well) were incubated overnight in the absence or presence of the SARS-CoV-2 S N M O defined peptide pool in the presence of anti-CD28 mAb. The number of cells secreting IFN-γ was analyzed by ELISpot and counted using MabtechIRIS.
Human PBMC from COVID-19 convalescent individuals (first two from the left from individuals previously confirmed COVID-19 positive with PCR, and third from the left from individual recovering from COVID-19 symptoms) and healthy control. Cells (350,000 cells/well) were incubated overnight in the absence or presence of the SARS-CoV-2 S N M O defined peptide pool in the presence of anti-CD28 mAb. The number of cells secreting IFN-γ was analyzed by ELISpot and counted using MabtechIRIS.
Human PBMC from COVID-19 convalescent individuals (first two from the left from individuals previously confirmed COVID-19 positive with PCR, and third from the left from individual recovering from COVID-19 symptoms) and healthy control. Cells (350,000 cells/well) were incubated overnight in the absence or presence of the SARS-CoV-2 S N M O defined peptide pool in the presence of anti-CD28 mAb. The number of cells secreting IFN-γ was analyzed by ELISpot and counted using MabtechIRIS.
Human PBMC from COVID-19 convalescent individuals (first two from the left from individuals previously confirmed COVID-19 positive with PCR, and third from the left from individual recovering from COVID-19 symptoms) and healthy control. Cells (350,000 cells/well) were incubated overnight in the absence or presence of the SARS-CoV-2 SNMO defined peptide pool in the presence of anti-CD28 mAb. The number of cells secreting IFN-γ and IL-2 was analyzed by FluoroSpot and counted using MabtechIRIS.
Datasheet/ProtocolSDS

Highlighted research
Published: October 28, 2024 | 18 minute read

Immunoassays for infectious disease research

Explore the role of immunoassays like ELISpot and FluoroSpot in infectious disease research. Discover how Mabtech's immunoassays enable researchers to study immune responses at the cellular level for diseases like TB, SARS-CoV-2, Malaria, HIV, and more.

Highlighted research, May 17, 2022

Third vaccine dose important for T cell response against Omicron

Three doses mRNA vaccine had better T cell responses than recipients of two doses. Mabtech IRIS and FluoroSpot Flex: Human IFN-γ/TNF-α/IL-2/Granzyme B were used to assess T cell immunity in mRNA vaccine recipients.

Highlighted research, December 16, 2021

SARS-CoV-2-specific immune responses in patients with autoimmune diseases

Patients with rheumatic diseases showed T cell responses comparable to healthy control. Patients with MS and after mRNA vaccination show different memory B cell IgG responses. SARS-CoV-2 specific immune responses in autoimmunity was analyzed using FluoroSpot, ELISpot Path, and Mabtech IRIS.

Highlighted research, December 2, 2021

Importance of studying SARS-CoV-2-specific memory B cells

When studying antibodies in circulation, remember that memory B cells might hide out of sight. In this study, detection of SARS-CoV-2-specific T and memory B cells 6 and 15 months after infection.

Highlighted research, November 24, 2021

Polyfunctional T cells with Mabtech IRIS

Study of development and persistence of virus-specific cellular and humoral immune responses, during the acute phase and two follow-ups after COVID-19 disease in hospitalized patients. Mabtech’s FluoroSpot Plus: Human IFN-γ/IL-2/TNF-α were analyzed with Mabtech IRIS.

Highlighted research, November 24, 2021

Polyfunctional T cells with Mabtech IRIS

Study of development and persistence of virus-specific cellular and humoral immune responses, during the acute phase and two follow-ups after COVID-19 disease in hospitalized patients. Mabtech’s FluoroSpot Plus: Human IFN-γ/IL-2/TNF-α were analyzed with Mabtech IRIS.

Highlighted research, June 30, 2020

T cell immunity in COVID-19

Much emphasis has been put on antibody responses, but also T cells are important in the context of COVID-19. In this study, the authors characterized SARS-CoV-2-specific T cell responses by using an extensive FACS panel, peptide stimulations, tetramer staining, and Mabtech IFN-γ ELISpot.

Highlighted research, May 30, 2020

B cell FluoroSpot for sensitive ASC detection

Mabtech IRIS and IgG/IgA/IgM FluoroSpot were used to study antibody-secreting plasma cells (ASCs) specific for the nucleocapsid (N) protein. FluoroSpot was shown to be more sensitive than e.g., ELISA.

Highlighted research, May 11, 2020

Longevity of immunity against SARS-CoV-2

Investigation of specific T cell responses to SARS-CoV 11 years after outbreak using Mabtech human IFN-γ ELISpot.
Loading publications...
1 / 3

PepPool: SARS-CoV-2 (S1), scanning